TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

DECEMBER 20, 2021

Data To Support Regulatory Filings in the United States. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., BERWYN, Pa.–(BUSINESS

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Cannabis Law Report

JULY 24, 2019

Examples of claims observed on your website and social media accounts in April 2019 that establish the intended use of your products as drugs include, but may not be limited to, the following: On your product webpage for CBD Disposable Vape Pen (Relieve): • “[F]or chronic pain.”. Chronic or arthritic pain.”. Chronic pain.

CBD 51

CBD Tincture Pets Chronic Pain 51

Project CBD

MAY 3, 2023

She is the medical director of Canna-Centers Wellness & Education and the clinical advisor to Cannformatics. She is also the author of Cannabis is Medicine: How Medical Cannabis and CBD are Healing Everything from Anxiety to Chronic Pain. But we may be on the cusp of having those trials, which would be very exciting.

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

The Cannigma

JANUARY 13, 2023

Treating migraine pain is one of the instances where inhaled cannabis consumption, such as smoking or vaping , is important for the right effects and speed of delivery. Edibles won’t produce the same experience, but topicals may be able to help, too. Topical cannabis products can also be useful, but research and data is very limited.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

NOVEMBER 10, 2021

The NIH has also engaged a firm to manufacture Leu-enkephalin (L-ENK), the active ingredient in Envelta and a firm to manufacture the Molecular Envelope Technology (MET) that is used to carry the L-ENK to the brain to promptly suppress pain. In October 2021, Virpax announced that a $1.87 About Virpax Pharmaceuticals.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

OCTOBER 6, 2021

With the additional funding recently secured by Virpax and the strengthening of our balance sheet, we are continuing to advance our product candidates and to move them through preclinical studies and into human clinical trials,” said Anthony Mack, Chairman and Chief Executive Officer of Virpax Pharmaceuticals.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Cannabis Law Report

OCTOBER 1, 2021

Virpax is developing branded, non-addictive pain management and neurological product candidates using its proprietary technologies to optimize and target drug delivery. Epoladerm™ is a topical diclofenac metered-dose spray film formulation being developed to manage acute musculoskeletal pain and osteoarthritis.

Research and Development 52

Research and Development Pharmaceutical Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 15, 2021

Our lead product candidate is Envelta™, which utilizes MET to deliver enkephalin nanoparticles for acute and chronic pain including pain associated with cancer. Epoladerm™ is a topical diclofenac spray film formulation being developed to manage osteoarthritis pain. On September 9, 2021, Jeffrey A.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Puff Puff Post

SEPTEMBER 16, 2019

Clinical toolkits to help navigate patient assessment and follow-ups. “A significant issue preventing the consideration of cannabinoid medicine by healthcare professionals is that the topic is not typically included in the medical school curriculum,” comments Dr. Mark Ware, Chief Medical Officer, Canopy Growth.

Programs 108

Programs Research and Development Education Treatment 108

The Cannigma

APRIL 8, 2021

CP: I’m going to say yes and it’s hard to tie this together, but there’s actually some really good animal, and a little bit of human data to support this. I postulate that that is correlated to our endocannabinoid system, which good data is now suggesting, is dysregulated in metabolic syndrome: obesity, diabetes, heart disease.

Medicine 108

Medicine Cannabinoids Cannabis THC 108

Cannabis Law Report

NOVEMBER 24, 2021

At the same time, the outlook on cannabis research data is largely positive. Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Data collection.

Research and Development 52

Research and Development Medicine Access Media 52

Puff Puff Post

SEPTEMBER 16, 2019

Clinical toolkits to help navigate patient assessment and follow-ups. “A significant issue preventing the consideration of cannabinoid medicine by healthcare professionals is that the topic is not typically included in the medical school curriculum,” comments Dr. Mark Ware, Chief Medical Officer, Canopy Growth.

Programs 40

Programs Research and Development Education Treatment 40

Cannabis Law Report

OCTOBER 17, 2019

Retailers such as Walgreens, CVS, Rite Aid, Kroger, Safeway, Nordstrom, and DSW are selling or plan to sell CBD-infused topical lotions, cosmetics, and even edibles where they are legally able to do so. Another researcher, New Frontier Data, pegged the global value of legal and illicit cannabis together at $340 billion in 2018.

Law 40

Law Seed-To-Sale Hemp Recreational 40

Cannabis Law Report

JUNE 30, 2019

Lou Correa (D-CA) that would require the VA to conduct clinical trials on the therapeutic potential of cannabis in the treatment of such service-related conditions as post-traumatic stress disorder and chronic pain. The panel also took up a bill sponsored by Rep. International.

Chronic Pain 40

Chronic Pain Legislation Treatment Programs 40